Phenol-based endoscopic ultrasound-guided celiac plexus neurolysis for East Asian alcohol-intolerant upper gastrointestinal cancer patients: A pilot study

Table 1 Patient characteristics and endoscopic ultrasound-guided celiac plexus neurolysis -related data

	Phenol	Ethanol	P value
Number of patients	6	16
Age (yr) [median (range)]	63 (52-74)	71 (47-83)	0.396
Gender (n) [male/female]	2/4	7/9	1
Primary site (n)			1
Pancreas/other	5/1	12/4
Treatment (n)			0.090
CRT/CT/NT	2/3/1	0/11/5
Direct invasion of celiac plexus (n)	1	7	0.350
NRS before CPN [median (range)]	5.0 (4-7)	5.5 (4-8)	0.472
History of narcotic use (n)	1	11	0.056
EUS-CPN technique			0.330
Central/CGN	3/3	4/12
Total amount of neurolytic agent (mL) [median (range)]	18.0 (13-20)	13.0 (3.5-20)	0.085

EUS-CPN: Endoscopic ultrasound-guided celiac plexus neurolysis; NRS: Numeric Rating Scale; CRT: Chemoradiotherapy; CT: Chemotherapy; NT: No therapy; CGN: Celiac ganglia neurolysis.